Active, not recruitingInterventionalPhase 2Last updated Jul 31, 2026

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants With Polycythemia Vera (PV)

Overview

ClinicalTrials.gov ID: NCT06985147
Lead Sponsor: Disc Medicine, IncINDUSTRY
Brief Summary: This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Study Type: Interventional

Status

Overall Status: Active, not recruiting
Start Date: Aug 12, 2025Actual
Primary Completion Date: Feb 2027Estimated
Completion Date: Feb 2029Estimated

Study Record Dates

First Submitted: May 7, 2025
First Submitted that Met QC Criteria: May 14, 2025
First Posted: May 22, 2025Actual
Last Update Submitted that Met QC Criteria: Jul 30, 2026
Last Update Posted: Jul 31, 2026Actual
Last Verified: Sep 2025

NCT05320198Recruiting

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT07187973Recruiting

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

NCT00595829Terminated

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

NCT05499013Active, not recruiting

Study to Assess SLN124 in Patients With Polycythemia Vera

NCT06050915Completed

A Study of DISC-3405 in Healthy Volunteers

NCT07012109Recruiting

Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)